Percutaneous MR imaging-guided laser-induced thermotherapy of hepatic metastases

被引:87
作者
Mack, MG
Straub, R
Eichler, K
Engelmann, K
Zangos, S
Roggan, A
Woitaschek, D
Böttger, M
Vogl, TJ
机构
[1] Univ Frankfurt, Dept Diagnost & Intervent Radiol, D-60590 Frankfurt, Germany
[2] LMTB gGMBH, D-12207 Berlin, Germany
来源
ABDOMINAL IMAGING | 2001年 / 26卷 / 04期
关键词
laser; laser-induced thermotherapy; minimal invasive therapy; MRI; liver metastases;
D O I
10.1007/s002610000197
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Many primary tumors may cause liver metastases, which are generally treated with surgical resection and/or chemotherapy. After resection of liver metastases in patients with colorectal carcinoma, 5-year survival rates are achieved in 25-38%, and two-thirds of patients will experience recurrent metastases. We examined percutaneous, minimally invasive, laser-induced thermotherapy (LITT) as an alternative outpatient procedure. Local tumor control rate and survival data were analyzed prospectively. Methods: Between June 1993 and August 2000, 7148 laser applications were performed in 1981 lesions in 705 consecutive patients and 1653 treatment sessions. The complications of the procedure were evaluated by clinical examination and magnetic resonance imaging (MRI) and computed tomography. Local tumor control was evaluated by plain and contrast-enhanced follow-up MRI using T1- and T2-weighted spin-echo and gradient-echo sequences every 3 months after treatment. Cumulative survival times were calculated using the Kaplan-Meier method. Results: The overall rate of complications and side effects was 7.5%. The rate of clinically relevant complications was 1.3%. Local tumor control rate after 3 months was 99.3%; 6 months after laser treatment, plain and contrast-enhanced MRI documented a local tumor control rate of 97.9%. In patients treated with MR-guided LITT for unresectable colorectal liver metastases, the mean survival was 41.8 months (95% confidence interval = 37.3-46.4 months). The 1-year survival rate was 93%, the 2-year survival rate was 74%, the 3-year survival rate was 50%, and the 5-year survival was 30%. In patients treated with LITT for liver metastases from breast cancer, the mean survival was 4.3 years (95% confidence interval = 3.6-5.0 years). Conclusion: In patients with liver metastases, local tumor destruction using minimally invasive, percutaneous LITT under local anesthesia results in improved clinical outcomes and survival rates and can be a potential alternative to surgical resection.
引用
收藏
页码:369 / 374
页数:6
相关论文
共 24 条
[1]   HEPATIC METASTASES - INTERSTITIAL LASER PHOTOCOAGULATION WITH REAL-TIME US MONITORING AND DYNAMIC CT EVALUATION OF TREATMENT [J].
AMIN, Z ;
DONALD, JJ ;
MASTERS, A ;
KANT, R ;
STEGER, AC ;
BOWN, SG ;
LEES, WR .
RADIOLOGY, 1993, 187 (02) :339-347
[2]   MR IMAGING HISTOPATHOLOGIC CORRELATION OF THERMAL-INJURIES INDUCED WITH INTERSTITIAL NDYAG LASER IRRADIATION IN THE CHRONIC MODEL [J].
ANZAI, Y ;
LUFKIN, RB ;
HIRSCHOWITZ, S ;
FARAHANI, K ;
CASTRO, DJ .
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1992, 2 (06) :671-678
[3]  
BUTLER J, 1986, SURG GYNECOL OBSTET, V162, P109
[4]   INTERSTITIAL PHOTOABLATIVE LASER THERAPY GUIDED BY MAGNETIC-RESONANCE-IMAGING FOR THE TREATMENT OF DEEP TUMORS [J].
CASTRO, DJ ;
SAXTON, RE ;
LUFKIN, RB .
SEMINARS IN SURGICAL ONCOLOGY, 1992, 8 (04) :233-241
[5]   MAGNETIC RESONANCE-GUIDED THERMAL SURGERY [J].
CLINE, HE ;
SCHENCK, JF ;
WATKINS, RD ;
HYNYNEN, K ;
JOLESZ, FA .
MAGNETIC RESONANCE IN MEDICINE, 1993, 30 (01) :98-106
[6]   FACTORS INFLUENCING SURVIVAL IN PATIENTS WITH HEPATIC METASTASES FROM ADENOCARCINOMA OF THE COLON OR RECTUM [J].
GOSLIN, R ;
STEELE, G ;
ZAMCHECK, N ;
MAYER, R ;
MACINTYRE, J .
DISEASES OF THE COLON & RECTUM, 1982, 25 (08) :749-754
[7]   RECURRENT TUMOR AFTER RESECTION OF HEPATIC METASTASES FROM COLORECTAL-CARCINOMA - LOCATION AND TIME OF DISCOVERY AS DETERMINED BY CT [J].
HARNED, RK ;
CHEZMAR, JL ;
NELSON, RC .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1994, 163 (01) :93-97
[8]   RESECTION OF THE LIVER FOR COLORECTAL-CARCINOMA METASTASES - A MULTI-INSTITUTIONAL STUDY OF LONG-TERM SURVIVORS [J].
HUGHES, KS ;
ROSENSTEIN, RB ;
SONGHORABODI, S ;
ADSON, MA ;
ILSTRUP, DM ;
FORTNER, JG ;
MACLEAN, BJ ;
FOSTER, JH ;
DALY, JM ;
FITZHERBERT, D ;
SUGARBAKER, PH ;
IWATSUKI, S ;
STARZL, T ;
RAMMING, KP ;
LONGMIRE, WP ;
OTOOLE, K ;
PETRELLI, NJ ;
HERRERA, L ;
CADY, B ;
MCDERMOTT, W ;
NIMS, T ;
ENKER, WE ;
COPPA, GF ;
BLUMGART, LH ;
BRADPIECE, H ;
URIST, M ;
ALDRETE, JS ;
SCHLAG, P ;
HOHENBERGER, P ;
STEELE, G ;
HODGSON, WJ ;
HARDY, TG ;
HARBORA, D ;
MCPHERSON, TA ;
LIM, C ;
DILLON, D ;
HAPP, R ;
RIPEPI, P ;
VILLELLA, E ;
SMITH, W ;
ROSSI, RL ;
REMINE, SG ;
OSTER, M ;
CONNOLLY, DP ;
ABRAMS, J ;
ALJURF, A ;
HOBBS, KEF ;
LI, MKW ;
HOWARD, T ;
LEE, E .
DISEASES OF THE COLON & RECTUM, 1988, 31 (01) :1-4
[9]  
JAFFE BM, 1968, SURG GYNECOL OBSTETR, V127, P1
[10]   NO TREATMENT OPTION FOR LIVER METASTASES FROM COLORECTAL ADENOCARCINOMA [J].
PALMER, M ;
PETRELLI, NJ ;
HERRERA, L .
DISEASES OF THE COLON & RECTUM, 1989, 32 (08) :698-701